In HBV-associated HCC, hepatitis B virus core antigen (HBcAg) delivers miR-135a-5p via sEVs, suppressing VAMP2 expression, thereby enhancing anti-apoptotic capacity and fostering drug resistance in HCC cells (60). This evidence concerns the gene VAMP2 and hepatocellular carcinoma.